Bloom Burton & Co. Upgrades Aurinia Pharmaceuticals (AUPH) to Buy (1)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts AUPH Hot Sheet
Price: $16.56 --0%
Rating Summary:
6 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Rating Summary:
6 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Join SI Premium – FREE
Bloom Burton & Co. analyst David Martin upgraded Aurinia Pharmaceuticals (NASDAQ: AUPH) from Hold (3) to Buy (1) with a price target of $21.00.
For an analyst ratings summary and ratings history on Aurinia Pharmaceuticals click here. For more ratings news on Aurinia Pharmaceuticals click here.
Shares of Aurinia Pharmaceuticals closed at $16.17 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades United Overseas Bank Ltd. (UOB:SP) (UOVEY) to Sell
- Fiserv (FISV) PT Raised to $59 at TD Cowen
- Amgen (AMGN) PT Raised to $470 at RBC Capital
Create E-mail Alert Related Categories
UpgradesRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
